Other languages IO Biotech, Inc.

Equities

IOBT

US4497781090

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
1.48 ^USD	-3.27%		+4.23%	-21.28%

26/04	IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	CI
15/04	IO Biotech Announces Marjan Shamsaei as Senior Vice President	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	27/04
IO Biotech Announces Marjan Shamsaei as Senior Vice President	15/04
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	09/04
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer	05/04
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting	07/03
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment	22/12
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	21/12
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
IO Biotech Appoints Helen Collins, Md, to Its Board of Directors	13/11
IO Biotech Completes Enrollment in Pivotal Phase 3 Trial in Advanced Melanoma	10/11
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma	10/11
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology Congress	23/23/23
IO Biotech Reports 'Encouraging' Data from Phase 2 Trial of IO102-IO103, Keytruda Combination to Treat Lung Cancer	12/23/12
IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors	11/23/11
IO Biotech Launching $75 Million Private Stock Placement; Shares Rise	07/23/07
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center	28/23/28
IO Biotech Names Dr. Qasim Ahmad as Chief Medical Officer	19/23/19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IO Biotech, Inc.

Equities

IOBT

US4497781090

Other languages

Filters